Grifols (NASDAQ:GRFS – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. dropped their target price on shares of Grifols from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Monday, October 26th. Zacks Research lowered shares of Grifols from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 3rd. Finally, Weiss Ratings raised shares of Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, November 4th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $9.00.
Check Out Our Latest Stock Report on Grifols
Grifols Stock Performance
GRFS opened at $8.69 on Friday. Grifols has a 52-week low of $6.96 and a 52-week high of $9.77. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.82 and a current ratio of 2.33. The firm’s 50-day moving average price is $7.75 and its 200-day moving average price is $7.99.
Institutional Trading of Grifols
Several large investors have recently made changes to their positions in the business. Flat Footed LLC raised its stake in shares of Grifols by 26.5% during the 1st quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock valued at $11,007,000 after buying an additional 287,867 shares during the last quarter. Tidal Investments LLC lifted its holdings in shares of Grifols by 9.8% in the 2nd quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company’s stock valued at $8,730,000 after buying an additional 109,612 shares during the period. Royal Bank of Canada boosted its stake in shares of Grifols by 15.4% in the first quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock worth $6,301,000 after buying an additional 104,850 shares during the last quarter. Quantinno Capital Management LP boosted its stake in shares of Grifols by 42.0% in the first quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company’s stock worth $2,829,000 after buying an additional 104,418 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in Grifols by 13.8% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 592,173 shares of the biotechnology company’s stock worth $4,193,000 after acquiring an additional 72,037 shares during the period.
About Grifols
Grifols is a global healthcare company headquartered in Barcelona, Spain, focused on developing and producing plasma-derived medicines and other healthcare products. Founded in 1909, the company has expanded from its origins in laboratory services into a business spanning plasma collection, biopharmaceuticals, diagnostics and hospital solutions. Its biopharmaceutical business collects and processes human plasma to make medicines, including immunoglobulins, albumin and coagulation factors. Grifols also supplies diagnostic products and services for transfusion medicine and offers products used in hospitals and clinical laboratories.
Recommended Stories
- Five stocks we like better than Grifols
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.
